AstraZeneca has signed an agreement whereby it will outsource most ofits information technology operations to IBM, in a deal worth $1.7 billion over seven years. As part of the agreement, 1,200 AstraZeneca staff in the UK, the USA and Sweden will transfer to IBM, which will provide a wide range of services in areas such as PC management, network and communications services (including e-mail), and computer operations support. The Anglo-Swedish firm noted that it will still retain control of its IT technical strategy and the development and support of its application systems.
Jon Symonds, AstraZeneca's chief financial officer, said the partnership will sharpen the firm's focus in areas such as e-business and informatics in R&D. He added that once the deal is finalized, the link-up with IBM will "provide better opportunities for personal development for these IT professionals, as well as significant cost savings."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze